These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 22520494)

  • 1. Response to a bolus of conivaptan in patients with acute hyponatremia after brain injury.
    Human T; Onuoha A; Diringer M; Dhar R
    J Crit Care; 2012 Dec; 27(6):745.e1-5. PubMed ID: 22520494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic effect of conivaptan bolus dosing in hyponatremic neurosurgical patients.
    Marik PE; Rivera R
    Pharmacotherapy; 2013 Jan; 33(1):51-5. PubMed ID: 23307545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
    Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit.
    Murphy T; Dhar R; Diringer M
    Neurocrit Care; 2009; 11(1):14-9. PubMed ID: 19123060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conivaptan for treatment of hyponatremia in neurologic and neurosurgical adults.
    Buckley MS; Patel SA; Hattrup AE; Kazem NH; Jacobs SC; Culver MA
    Ann Pharmacother; 2013 Sep; 47(9):1194-200. PubMed ID: 24259735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.
    Breshears JD; Jiang B; Rowland NC; Kunwar S; Blevins LS
    Clin Neurol Neurosurg; 2013 Nov; 115(11):2358-61. PubMed ID: 24041963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
    Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
    Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia.
    Annane D; Decaux G; Smith N;
    Am J Med Sci; 2009 Jan; 337(1):28-36. PubMed ID: 19057376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bolus of conivaptan lowers intracranial pressure in a patient with hyponatremia after traumatic brain injury.
    Dhar R; Murphy-Human T
    Neurocrit Care; 2011 Feb; 14(1):97-102. PubMed ID: 20440600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia.
    Ghali JK; Koren MJ; Taylor JR; Brooks-Asplund E; Fan K; Long WA; Smith N
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2145-52. PubMed ID: 16522696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
    Der-Nigoghossian C; Lesch C; Berger K
    Pharmacotherapy; 2017 May; 37(5):528-534. PubMed ID: 28295447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intravenous conivaptan in neurosurgical patients with hyponatremia from syndrome of inappropriate antidiuretic hormone secretion.
    Potts MB; DeGiacomo AF; Deragopian L; Blevins LS
    Neurosurgery; 2011 Aug; 69(2):268-73. PubMed ID: 21792136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extreme correction of hyponatremia in a patient treated with intravenous conivaptan.
    Sughrue ME; McDermott M; Blevins LS
    J Clin Neurosci; 2010 Oct; 17(10):1331-4. PubMed ID: 20594854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of conivaptan for the treatment of symptomatic hyponatremia in a patient with acute decompensated heart failure.
    Pinner NA; Oliphant CS; Hopkins JP
    Am J Health Syst Pharm; 2010 Jun; 67(12):1011-5. PubMed ID: 20516472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of oral vasopressin V2 receptor antagonist for hyponatremia in acute brain injury.
    Jeon SB; Choi HA; Lesch C; Kim MC; Badjatia N; Claassen J; Mayer SA; Lee K
    Eur Neurol; 2013; 70(3-4):142-8. PubMed ID: 23887035
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.
    Verbalis JG; Zeltser D; Smith N; Barve A; Andoh M
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):159-68. PubMed ID: 18034777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous conivaptan.
    Moen MD; Keating GM
    Am J Cardiovasc Drugs; 2008; 8(5):341-8; discussion 349. PubMed ID: 18828645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
    J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.